hyperCORE International: Company Profile

Background

Overview

hyperCORE International, established in 2019, is a leading global network of independent clinical research site companies. The organization comprises over 70 active research sites across five countries on two continents, making it the second-largest clinical research site organization worldwide. Collectively, its member companies have more than 100 years of combined experience, having completed over 9,000 studies involving more than 140,000 patients.

Mission and Vision

hyperCORE International's mission is to accelerate clinical research through innovative partnerships between industry-leading clinical trial companies, ultimately improving the health and well-being of diverse populations globally. The organization envisions modernizing the fragmented and inefficient research site model by integrating strengths and sharing best practices among its members.

Primary Area of Focus and Industry Significance

The organization specializes in providing Phase I-IV clinical trial services, encompassing a wide range of therapeutic areas. Its significant global presence and extensive experience position hyperCORE International as a pivotal entity in the clinical research industry, facilitating the evaluation of new drugs and treatments across diverse patient populations.

Key Strategic Focus

Core Objectives

• Accelerated Clinical Research: Streamlining clinical trial processes to expedite the development of new therapies.

• Global Expansion: Enhancing the network's reach to include diverse patient populations across multiple continents.

• Operational Excellence: Implementing standardized practices to ensure high-quality data and efficient study execution.

Specific Areas of Specialization

hyperCORE International's member sites possess expertise in various therapeutic areas, including oncology, infectious diseases, central nervous system disorders, gastroenterology, cardiovascular health, metabolic conditions, and general medicine.

Key Technologies Utilized

• Telehealth Integration: Employing virtual visits and remote monitoring to enhance patient engagement and data collection.

• Decentralized Clinical Trials (DCT): Implementing DCT methodologies to broaden accessibility and simplify trial logistics.

• Data Analytics Platforms: Utilizing advanced data analysis tools to monitor study progress and ensure data integrity.

Primary Markets and Conditions Targeted

The organization focuses on global markets, conducting trials in North and South America, Europe, and Asia. It addresses a broad spectrum of conditions, from common diseases to rare and complex disorders.

Financials and Funding

Funding History

hyperCORE International operates as a privately held entity, and specific details regarding its funding history, total funds raised, and notable investors are not publicly disclosed.

Utilization of Capital

The capital is primarily allocated towards expanding the network, enhancing technological infrastructure, and supporting the integration of new partner sites to strengthen the organization's global presence and operational capabilities.

Pipeline Development

Key Pipeline Candidates

hyperCORE International's member sites are involved in a diverse array of clinical trials across various phases, focusing on developing treatments for conditions such as:

• Oncology: Investigating novel cancer therapies.

• Infectious Diseases: Developing vaccines and treatments for emerging pathogens.

• Neurology: Exploring interventions for neurological disorders.

• Cardiology: Assessing new cardiovascular treatments.

Stages of Clinical Trials

The organization conducts trials across all phases, from early-phase (I/II) studies to late-phase (III/IV) trials, ensuring comprehensive evaluation of therapeutic candidates.

Target Conditions

hyperCORE International addresses a wide range of conditions, including but not limited to:

• Oncological Disorders

• Infectious Diseases

• Neurological Conditions

• Cardiovascular Diseases

• Metabolic Disorders

Anticipated Milestones

While specific timelines for individual trials are not publicly disclosed, the organization aims to achieve rapid study startup, competitive enrollment, and timely data reporting to meet the needs of sponsors and contribute to the advancement of medical research.

Technological Platform and Innovation

Proprietary Technologies

hyperCORE International leverages proprietary platforms for:

• Study Management: Centralized systems for protocol development, site selection, and monitoring.

• Data Collection: Electronic data capture (EDC) systems ensuring accurate and timely data acquisition.

• Patient Engagement: Mobile applications and portals facilitating patient recruitment, retention, and communication.

Significant Scientific Methods

• Decentralized Clinical Trials (DCT): Implementing DCT methodologies to broaden accessibility and simplify trial logistics.

• Telehealth Integration: Utilizing virtual visits and remote monitoring to enhance patient engagement and data collection.

• Data Analytics Platforms: Employing advanced data analysis tools to monitor study progress and ensure data integrity.

Leadership Team

Executive Profiles

• Gwen Welty: Executive Director

• Nicholas Focil: President

• Maria Ximena Graber, MD: Vice President

• Mark Scullion: Secretary

• Olivia McIver: Treasurer

Professional Backgrounds and Contributions

• Gwen Welty: As Executive Director, Ms. Welty oversees the strategic direction and operational management of hyperCORE International, ensuring alignment with the organization's mission and objectives.

• Nicholas Focil: Serving as President, Mr. Focil leads the organization's growth initiatives, focusing on expanding the network and fostering partnerships with sponsors and CROs.

• Maria Ximena Graber, MD: Dr. Graber contributes her medical expertise to guide clinical operations and ensure the scientific integrity of the trials conducted.

• Mark Scullion: As Secretary, Mr. Scullion manages organizational governance and compliance, maintaining the integrity of the network's operations.

• Olivia McIver: Serving as Treasurer, Ms. McIver oversees financial management, ensuring the organization's fiscal health and sustainability.

Competitor Profile

Market Insights and Dynamics

The global clinical research industry is experiencing significant growth, driven by the increasing demand for new therapies and the expansion of personalized medicine. Organizations like hyperCORE International play a crucial role in accelerating the development of new treatments by providing efficient and diverse clinical trial sites.

Competitor Analysis

Key competitors in the clinical research site network space include:

• Nucleus Network: A privately held organization with 250-500 employees, specializing in Phase I clinical trials.

• Promedica International: A privately held company with 1-25 employees, focusing on clinical research services.

• OWL Oncology Research: A company with 100-200 employees, specializing in oncology research.

These competitors offer similar services but differ in scale, therapeutic focus, and geographic reach.

Strategic Collaborations and Partnerships

hyperCORE International has established several strategic partnerships to enhance its capabilities:

• Aventiv Research: Added to the network in March 2021, expanding Phase I clinical trial services.

• MOORE Clinical Research: Joined in November 2020, contributing expertise in dermatology.

• Atlas Clinical Research: Became a partner in April 2025, enhancing the network's reach and capabilities.

Operational Insights

hyperCORE International's integrated model allows for streamlined operations, including centralized budgeting, single-point contracts, and shared platforms, which enhance efficiency and reduce administrative burdens for sponsors and CROs.

Strategic Opportunities and Future Directions

Strategic Roadmap

hyperCORE International aims to:

• Expand Global Presence: By adding new partner sites in underrepresented regions.

• Enhance Technological Integration: Implementing advanced data analytics and patient engagement tools.

• Diversify Therapeutic Expertise: Entering new therapeutic areas to meet evolving market needs.

Future Business Directions

The organization plans to focus on:

• Decentralized Clinical Trials: Expanding DCT capabilities to improve patient access and retention.

• Patient-Centric Approaches: Developing strategies to enhance patient recruitment and retention.

• Operational Excellence: Continuously improving processes to reduce study timelines and costs.

Opportunities for Expansion

hyperCORE International is exploring opportunities to:

• Form New Partnerships